Amyloid Beta-directed Antibody Interactions [MoA] - N0000193950

Name: Table of NDC products with amyloid beta-directed antibody interactions
Creator: U.S. Food & Drug Administration
License: https://creativecommons.org/licenses/by-nc-sa/4.0/

Pharmacologic Class Information

Pharmacologic Code	N0000193950
Pharmacologic Name	Amyloid Beta-directed Antibody Interactions
Pharmacologic Uses	amyloid beta-directed antibody
Pharmacologic Concept	Mechanisms of Action - [MoA]
Pharmacologic Concept Description	This concept refers to the mechanism of action pharmacologic action at the receptor, membrane, or tissue level. In MED-RT, molecular, subcellular, or cellular effects of drug generic ingredients, organized into a chemical function classification hierarchy, beneath the "Cellular or Molecular Interactions" concept.

NDC Products with Amyloid Beta-directed Antibody Interactions

The table contains 3 products whose active ingredient are classified under the same pharmacologic class Amyloid Beta-directed Antibody Interactions [MoA].

NDC	Proprietary Name	Non-Proprietary Name	Dosage Form	Route Name	Company Name	Status
62856-212	Leqembi	Non-Proprietary Name: Lecanemab	Injection, Solution	Intravenous	Eisai Inc.	ACTIVE
62856-215	Leqembi	Non-Proprietary Name: Lecanemab	Injection, Solution	Intravenous	Eisai Inc.	ACTIVE
62856-220	Lecanemab Autoinjector	Non-Proprietary Name: Lecanemab-irmb	Injection, Solution	Subcutaneous	Eisai Inc.	ACTIVE